Comparing Delcath Systems (NASDAQ:DCTH) & Axonics (NASDAQ:AXNX)

Delcath Systems (NASDAQ:DCTHGet Free Report) and Axonics (NASDAQ:AXNXGet Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Insider and Institutional Ownership

85.2% of Delcath Systems shares are held by institutional investors. Comparatively, 99.0% of Axonics shares are held by institutional investors. 21.1% of Delcath Systems shares are held by company insiders. Comparatively, 1.9% of Axonics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Delcath Systems and Axonics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems 0 0 4 0 3.00
Axonics 0 1 10 0 2.91

Delcath Systems presently has a consensus price target of $17.25, indicating a potential upside of 254.94%. Axonics has a consensus price target of $76.36, indicating a potential upside of 31.66%. Given Delcath Systems’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Delcath Systems is more favorable than Axonics.

Valuation & Earnings

This table compares Delcath Systems and Axonics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Delcath Systems $2.64 million 28.15 -$36.51 million ($3.13) -1.55
Axonics $273.70 million 10.69 -$59.70 million ($0.67) -86.57

Delcath Systems has higher earnings, but lower revenue than Axonics. Axonics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Delcath Systems has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Axonics has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.


This table compares Delcath Systems and Axonics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Delcath Systems -1,258.21% N/A -147.89%
Axonics -10.06% -5.60% -4.94%


Delcath Systems beats Axonics on 8 of the 14 factors compared between the two stocks.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About Axonics

(Get Free Report)

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with's FREE daily email newsletter.